Other

Memorial Sloan Kettering Cancer Center

Icahn School of Medicine at Mount Sinai

The Simons Center for Systems Biology at the Institute for Advanced Study

Michael Laessig

Taha Merghoub

Jedd David Wolchok

Arnold J Levine

Timothy A Chan

Benjamin D Greenbaum

Steven D Leach

Marta Luksza

Vinod P Balachandran

Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency Xin the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.

Neoantigens and uses thereof for treating cancer

Growing community of inventors

Cologne, Germany

Michael Laessig